Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Lyell Immunopharma, Inc. (LYEL) is a Biotechnology company based in US with a market capitalization of $321.3M. Revenue declined 41.0% year-over-year and free cash flow was negative at -$150.8M. This page tracks LYEL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 300 employees · IPO Jun 17, 2021
Valuation
Valuation & price
$17.92as of May 17, 2026· -53.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.29
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$321.3M
Market cap
-41.0%
Revenue growth (YoY)
-31952.8%
Gross margin
-$150.8M
Free cash flow (USD)
-$205.3M
Net debt
Net cash position
30.7%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
7
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 6, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJul 20, 2026Filing
Insider Sell $137Innovative Cellular Therapeutics Holdings Ltd · 10% Owner · $137
- Insider sellJul 17, 2026Filing
Insider Sell $137Innovative Cellular Therapeutics Holdings Ltd · 10% Owner · $137.3
- FinancingJul 13, 2026Filing
Securities Registration
- Insider sellJun 15, 2026Filing
Insider Sell $4KBulis Veronica Sanchez · VP, Corporate Controller · $4.1K
- Insider sellJun 15, 2026Filing
Insider Sell $2KHill Stephen J. · Chief Operating Officer · $1.7K
- Insider sellJun 15, 2026Filing
Insider Sell $2KLee Gary K. · Chief Scientific Officer · $2.5K
- Insider sellJun 15, 2026Filing
Insider Sell $7KSeely Lynn · Director, President and CEO · $7.3K
- 8-K eventJun 15, 2026Filing
Annual Meeting Results
- Insider sellJun 11, 2026Filing
Insider Sell $25KShook David · Chief Medical Officer · $25K
- 8-K eventMay 6, 2026Filing
Earnings Release
Questions
Frequently asked questions
What is Lyell Immunopharma, Inc.'s market cap?
Lyell Immunopharma, Inc. (LYEL) has a market capitalization of $321.3M.
What is LYEL's P/E ratio?
A meaningful P/E ratio is not available for LYEL — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is LYEL's price-to-book (P/B) ratio?
LYEL trades at 1.29 times book value per share.
Are insiders buying LYEL stock?
SEC Form 4 filings show no open-market insider buys at Lyell Immunopharma, Inc. in the last 90 days (7 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.